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be used by health care decision makers to identify patients who are most likely to be 
non-compliant with dyslipidemia therapy and help focus medication compliance 
efforts. A secondary analysis using corresponding lab data is projected.
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OBJECTIVES: To compare dual-eligible patient out-of-pocket costs, adherence (medi-
cation possession ratio), persistence, and average number of gap days in therapy before 
and after Medicaid patients enrolled in Medicare Part D. METHODS: This study 
employed a quasi-experimental, repeated measures design. Study population included 
1734 Texas dual-eligible beneﬁciaries who had prescriptions ﬁlled in Texas indepen-
dent community pharmacies between January 2005 and September 30, 2006. 
RESULTS: Average patient out-of-pocket costs increased from $0.39 per claim under 
Medicaid to $13.36 per claim under Medicare Part D. Patient MPR increased from 
75.71% during the Medicaid period to 79.37% during the Medicare period. Linear 
mixed model analysis showed that patient’s MPR increased by 3.66% when patients 
were enrolled under Medicare. Patients were persistent to their drug therapy for an 
average of 151.76 days under Medicaid and days of persistence increased to 159.75 
days during the Medicare period. Linear mixed model analysis showed that patients 
were persistent for 7.99 extra days after they were enrolled in Medicare Part D. 
Average number of gap days in therapy during the Medicaid period was 11.91 days 
and decreased to 8.38 days during the Medicare period. Linear mixed model analysis 
showed that average number of gap days in therapy decreased by 3.52 days when 
patients were enrolled in Medicare Part D. Linear mixed model analysis and linear 
regression analysis showed that as patient out-of-pocket costs increased, patient medi-
cation possession ratio and persistence increased and average number of gap days in 
therapy decreased. CONCLUSIONS: These results suggest that dual-eligible beneﬁ-
ciary’s medication utilization increased after implementation of Medicare Part D. 
Based on these results it can be concluded that higher out-of-pocket costs for dual-
eligible beneﬁciaries under Medicare Part D did not have a negative impact on their 
drug adherence and persistence.
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OBJECTIVES: To investigate the impact of the coverage gap in the Medicare Part D 
program on statin medication adherence. METHODS: A pharmacy claims database 
from a national pharmacy beneﬁt management company was used for this retrospec-
tive analysis. The sample includes Medicare Part D patients 65 years and older who 
1) used statins in both 2007 and 2008, and 2) entered the coverage gap (donut hole), 
but did not reach the catastrophic phase in 2008. Adherence was measured by a 
dummy variable indicating whether the proportion of days covered was greater than 
or equal to 0.8. A difference-in-differences regression analysis was used to evaluate 
the effect of the coverage gap by comparing adherence to statins before and after the 
start of the donut hole. RESULTS: A total of 26,686 patients were identiﬁed. Beneﬁ-
ciaries were mostly women (55.5%) with an average age of 75 years. Patients in the 
study were divided into three groups based on level of coverage in the donut hole: no 
coverage (N = 4,984), generic drug coverage (N = 6,063), or generic and brand drug 
coverage (N = 15,639). After patients entered the donut hole, the average 30-day 
co-payment for statin medications increased notably for beneﬁciaries who had no drug 
coverage ($21.62 to $49.72) or generic only coverage ($22.22 to $42.04), but 
decreased for those with generic and brand drug coverage ($20.12 to $16.63) Com-
pared to beneﬁciaries with both generic and brand medication coverage, beneﬁciaries 
with no coverage (OR = 0.581, p < 0.0001, 95% CI 0.525–0.645) and beneﬁciaries 
with only generic medication coverage (OR = 0.662, p < 0.0001, 95% CI 0.601–0.728) 
were less likely to be adherent to statin medications after entering the donut hole. 
CONCLUSIONS: Medicare beneﬁciaries with no coverage or generic only coverage 
were less likely than those with a more comprehensive gap coverage to be adherent 
to statins after entering the donut hole.
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OBJECTIVES: Despite the beneﬁts of lipid lowering therapies (LLT), adherence to 
LLT remains poor. This review aims to summarize and assess evidence from prior 
research on the association between adherence to LLT and cholesterol outcomes 
(cholesterol levels and/or goal attainment). METHODS: We searched PubMed data-
base for research articles written in English and published between January 1, 2000 
and December 31, 2009 using combinations of the following terms: “adherence,” 
“compliance,” “statin,” and “lipid lowering”. Retrieved articles were included for 
review if they met the criterion of adherence/compliance as a predictor of cholesterol 
outcomes (e.g., LDL-C, HDL-C, or TC). RESULTS: The automated literature search 
yielded 527 studies, 8 of which met the inclusion criteria. Despite that a majority of 
studies examined adherence to LLT, only a few included cholesterol outcomes. A total 
of 519 studies were excluded: 340 for being off topic, 5 for having no adherence 
measure, and 174 for having no cholesterol measures reported as an outcome. This 
review initially sought to quantify the effect of adherence on cholesterol outcomes; 
however, adherence measures and methods varied greatly among the 8 studies and 
made data synthesis challenging. Heterogeneous methodologies were used for adher-
ence measures, including medication possession ratio (MPR), medication event moni-
toring system (MEMS), adherence to therapy index (ATI), continuous measure of 
medication gaps (CMG) and pill counting. Regardless of how adherence was deﬁned, 
better adherence was associated with improved cholesterol outcomes (lower LDL-C 
or TC or higher HDL-C levels compared to their respective baseline levels). CONCLU-
SIONS: Few studies evaluated both adherence to LLT and cholesterol outcomes and 
various methodologies were used for adherence measurements. Further studies assess-
ing compliance and objective clinical endpoints are needed. Health care providers 
should monitor medication adherence and develop effective interventions to improve 
adherence given the evidence on improved cholesterol outcomes as a result of increased 
adherence.
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OBJECTIVES: To measure the impact of illness burden and medication beliefs on 
medication compliance of elderly with hypertension using a tool that pictorially rep-
resents the burden of illness on self. METHODS: A cross-sectional research design, 
utilizing convenience sampling strategies and self-administered surveys of elderly 
hypertensive residents living in New York City senior care centers. Medication compli-
ance was measured using Morisky’s test, medication beliefs were measured using 
beliefs about medication questionnaire (BMQ), and illness burden was operationalized 
by implementing Pictorial Representation of Illness and Self Measure- Revised II 
(PRISM-RII) instrument. PRISM is a novel and visual measurement tool of suffering 
that consists of two components, namely, self illness separation (SIS) and illness 
perception measure (IPM).Additionally, two index scores, namely World Health Orga-
nization (WHO-5) wellbeing score and Suffering Question (SQ) scores were also 
computed to further examine interrelationships among study variables. RESULTS: 
About 33% of the 120 hypertensive elderly cohorts who responded to the survey were 
found to be noncompliant with their blood pressure medications. Morisky’s score 
correlated signiﬁcantly and positively with both BMQ differential scores (r = −0.303, 
p = 0.001) and SIS component scores (r = −0.425, p = 0.000) respectively. General 
Overuse (GO) scores and IPM component scores correlated positively with Morisky’s 
score (r = 0.347 & 0.440, p = 0.000). SIS correlated positively with WHO-5 (r = 
0.142, p = 0.126) and negatively with IPM (r = −0.841, p = 0.000). CONCLUSIONS: 
Beliefs about the beneﬁts of taking medications outweigh the costs and risks of taking 
them. Higher perceived illness burden in hypertension translates into lower medication 
compliance in elderly. PRISM-RII may be a useful measure of illness burden in compli-
ance research in elderly populations. The study underscores the importance of incor-
porating patient perceptions about medications and illness burden into decisions 
involving hypertension management.
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OBJECTIVES: To identify the most effective interventions to improve patient compli-
ance with lipid lowering medications. METHODS: A systematic review was conducted 
using Medline, Cumulative Index to Nursing and Allied Health Literature, EMBASE, 
Cochrane Library, and references of review articles, and meta-analyses. Abstracts of 
studies published between 1999 and 2009, irrespective of language that included the 
terms: hyperlipidemia, hypercholesterolemia, lipid lowering medications and adher-
ence, compliance, and interventions were screened. Studies with incomplete informa-
tion, lack of adherence measure, overviews and letters to editors were excluded. Full 
articles of studies on interventions that reported the use of a comparator group and 
reported quantitative data on compliance were included. Two independent researchers 
reviewed papers, and disagreements were agreed by consensus. A standardized data 
extraction form was used to record details on study design, objectives, randomization, 
blinding, comparator group, type of intervention, outcomes, population, follow up, 
ethics approval, sample size, statistical analysis and results. A quality score was cal-
culated using the Downs modiﬁed scale. RESULTS: Of 130 titles, 79 abstracts were 
screened and only 15 studies fulﬁlled the inclusion criteria. Study heterogeneity pre-
cluded a quantitative meta-analysis. Most interventions improved drug compliance 
from 15% for single interventions to 27% for complex interventions. Most studies 
focused on pharmacist-led interventions, and the most effective included the use of 
telephone reminders, card reminders, brochures, and booklets. All interventions were 
able to reduce LDL and/or total cholesterol. Average index quality score was 40%. 
CONCLUSIONS: Interventions focused on improving compliance reduce LDL and 
total cholesterol. The most effective interventions to improve compliance with lipid 
lowering medications are complex, multi-factorial interventions. However, reports 
have variable quality.
